UnitedHealth Stock And 2 Dividend Names For Investors Seeking Stability

With US bankruptcy filings up 12% year over year and recession warnings growing louder in 2026, many investors are wondering where to find steadier ground without sitting entirely in cash. Rising credit stress and a narrow AI driven market create both risk and opportunity. This article walks through three dividend focused stocks exposed to these trends and explains how each may factor into portfolio decisions in the current environment.

The three stocks covered next are just a small sample of this idea. The full screen surfaces 30 more U.S. dividend companies that share similar defensive traits and have their own compelling stories. To see the complete list and start filtering for your highest conviction dividend plays, head straight to the Defensive, High-Quality Dividend Stocks screener.

Abbott Laboratories (ABT)

Abbott Laboratories is a global healthcare company that develops and sells diagnostics, medical devices, nutrition products, and branded generic pharmaceuticals, which fits the screener’s focus on defensive, income oriented healthcare stocks. It generates most of its revenue from Medical Devices at about US$22.5b, followed by Diagnostic Products at roughly US$10.0b, Nutritional Products at about US$8.3b, and Established Pharmaceutical at around US$5.8b, with only a small contribution from other activities. The company is large, with a market cap of about US$191.0b.

Investors looking for income that can potentially hold up when credit markets are under pressure may find Abbott Laboratories worth a closer look. The company combines a multi decade dividend record with a broad healthcare footprint in devices, diagnostics, and nutrition. This diversification can help smooth demand when other sectors feel a slowdown. At the same time, margins have recently come under pressure and debt levels are not low, so the dividend profile depends on management executing on new products such as FreeStyle Libre and emerging market pharmaceuticals while keeping funding costs in check. The gap between current pricing and some fair value estimates adds another angle that dividend focused investors may want to examine further.

Abbott Laboratories’ multi decade dividend story and broad healthcare mix might be masking an underappreciated twist. Get the 3 key rewards and 2 important warning signs that could reshape how you see its payout resilience and debt pressure.

Build your own dividend and healthcare shortlist

Abbott Laboratories and the two other stocks in this article all came from a single screen, but the real advantage comes when you tailor the filters yourself. Use our flexible Screener to mix valuation, dividend, quality, and risk criteria that fit your style, or start with any of our curated Investing Ideas.

Elevance Health (ELV)

Elevance Health is a large US health benefits company that fits the defensive dividend theme by collecting recurring premiums across commercial, Medicare, Medicaid, and specialty plans, then layering on pharmacy and care management services through its Carelon units. Most of its roughly US$201.1b in revenue comes from Health Benefits at about US$169.3b, with CarelonRx adding around US$44.5b and Carelon Services about US$29.7b, partly offset by segment eliminations. The company has a market cap of about US$84.6b, putting it firmly in the large cap camp.

Elevance Health offers a mix of recurring health insurance premiums, expanding care services, and a dividend track record that fits what many investors look for when bankruptcy headlines start to rise. The company is leaning hard into data, AI and value based care to keep medical costs in check and support margin recovery, even as Medicaid and ACA pressures, regulatory shifts and acquisition integration risks create real execution tests. With a large Carelon services arm, capital returns through dividends and buybacks, and signs of improving profitability in recent quarters, Elevance Health is the kind of business where a closer look at how those moving parts fit together could change how you rank it within a defensive income portfolio.

Elevance Health’s push into data driven care and AI backed cost control could be changing the story faster than many dividend investors realize. Read the analyst forecasts for Elevance Health to see what that shift might be setting up next.

UnitedHealth Group (UNH)

UnitedHealth Group is a large health care company that combines a traditional insurer, UnitedHealthcare, with the Optum services platform, which fits the screener’s focus on defensive, income oriented healthcare stocks. It generates most of its revenue from UnitedHealthcare at about US$346.5b, with Optum Rx around US$155.2b, Optum Health about US$100.0b and Optum Insight roughly US$19.7b, partly offset by segment adjustments and eliminations. The company has a market cap of about US$355.1b, putting it among the biggest US healthcare stocks.

Investors watching bankruptcy headlines and recession talk may find UnitedHealth Group worth attention as a large, diversified health insurer with a 2.36% dividend yield and a long record of regular payouts. The company is working to improve margins through technology and value based care programs, even as it deals with pressure from changing Medicare member profiles, high cost specialty drugs and regulatory scrutiny around Medicare billing and funding models. With profit margins currently around 3.1% and the stock trading well below some fair value estimates, the balance between near term margin risk and the potential benefits of its Optum platform and Medicare reset is where the real story lies for dividend focused investors who want to stress test their defensive holdings.

UnitedHealth Group’s 3.1% margin and massive Optum platform hint that the real story may be about resilience rather than stress. Read the analysis report for UnitedHealth Group to see what that margin reset could quietly be setting up next.

Seeking Fresh Alternatives Before Momentum Flips

New ideas move fast. By the time most investors react, the real breakout or sharp drop is already flying past. Scan these focused stock lists while it matters and get in early.

• Catch early leadership in smaller companies that already produce profits and use AI as a tool rather than a story through the curated 75 profitable AI stocks that aren't just burning cash.
• Hunt for resilient payers that aim to keep distributions flowing even when headlines turn negative using the curated 11 dividend fortresses.
• Track potential beneficiaries of rising demand for secure transaction rails and tokenized assets inside the focused 20 cryptocurrency and blockchain stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com